Omnicell, Inc. (OMCL) Income Statement Analysis

See more : Sun Brothers Development Co., Limited (3489.TWO) Income Statement Analysis – Financial Results

Complete financial analysis of Omnicell, Inc. (OMCL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Omnicell, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.

You may be interested

Man Wah Holdings Limited (MAWHF) Income Statement Analysis – Financial Results
Hanwha Investment & Securities Co., Ltd. (003535.KS) Income Statement Analysis – Financial Results
Sulliden Mining Capital Inc. (SULMF) Income Statement Analysis – Financial Results
Tantalus Systems Holding Inc. (GRID.TO) Income Statement Analysis – Financial Results
Xiamen Xindeco Ltd. (000701.SZ) Income Statement Analysis – Financial Results

Omnicell, Inc. (OMCL)

Industry: Medical - Healthcare Information Services

Sector: Healthcare

Website: https://www.omnicell.com

About Omnicell, Inc.

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000
Revenue	1.15B	1.30B	1.13B	892.21M	897.03M	787.31M	716.17M	692.62M	484.56M	440.90M	380.59M	314.03M	245.54M	222.41M	213.46M	251.87M	213.08M	154.71M	121.52M	123.94M	102.13M	87.69M	86.90M	67.37M
Cost of Revenue	647.18M	706.96M	577.37M	478.92M	460.12M	414.98M	394.08M	378.82M	236.63M	207.04M	177.19M	143.47M	109.75M	104.49M	108.24M	123.23M	99.77M	69.19M	54.51M	52.03M	42.46M	36.42M	32.77M	26.58M
Gross Profit	499.93M	588.99M	554.65M	413.29M	436.91M	372.33M	322.09M	313.80M	247.93M	233.86M	203.40M	170.55M	135.78M	117.92M	105.22M	128.63M	113.31M	85.52M	67.01M	71.91M	59.67M	51.27M	54.13M	40.79M
Gross Profit Ratio	43.58%	45.45%	49.00%	46.32%	48.71%	47.29%	44.97%	45.31%	51.17%	53.04%	53.44%	54.31%	55.30%	53.02%	49.29%	51.07%	53.18%	55.28%	55.14%	58.02%	58.42%	58.47%	62.29%	60.55%
Research & Development	97.12M	104.97M	75.72M	70.16M	68.64M	64.84M	66.02M	57.80M	35.16M	27.80M	29.11M	23.73M	22.04M	21.01M	17.57M	18.20M	15.05M	11.22M	9.61M	9.11M	8.95M	9.97M	11.03M	11.27M
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	138.30M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	700.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	434.59M	486.34M	389.43M	307.61M	289.92M	263.10M	250.31M	249.52M	167.58M	156.48M	139.00M	119.75M	97.52M	86.23M	85.67M	93.10M	80.04M	65.04M	59.70M	52.08M	42.78M	44.77M	43.68M	46.14M
Other Expenses	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-178.00K	-99.00K	0.00	0.00	1.32M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	534.80M	591.31M	465.15M	377.77M	358.56M	327.94M	316.33M	307.32M	202.74M	184.28M	168.10M	143.47M	119.56M	107.23M	103.24M	111.29M	95.09M	76.27M	69.31M	61.19M	51.73M	54.74M	54.71M	57.41M
Cost & Expenses	1.18B	1.30B	1.04B	856.68M	818.68M	742.92M	710.41M	686.14M	439.37M	391.32M	345.29M	286.94M	229.31M	211.72M	211.47M	234.53M	194.86M	145.45M	123.82M	113.22M	94.19M	91.16M	87.48M	83.99M
Interest Income	0.00	130.00K	23.50M	6.18M	4.42M	0.00	0.00	0.00	0.00	0.00	30.00K	77.00K	266.00K	424.00K	619.00K	3.42M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	130.00K	22.39M	2.10M	5.80M	0.00	0.00	0.00	0.00	0.00	122.00K	29.00K	62.00K	4.00K	15.00K	15.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	95.56M	99.17M	84.93M	71.60M	64.12M	51.35M	51.51M	58.36M	25.64M	20.27M	18.37M	13.33M	7.98M	8.62M	9.43M	8.95M	4.60M	3.72M	4.20M	4.09M	3.50M	3.02M	3.72M	3.66M
EBITDA	60.69M	96.85M	174.44M	107.12M	78.35M	95.74M	62.66M	64.84M	71.88M	69.86M	53.66M	40.45M	24.13M	18.58M	10.64M	29.69M	22.83M	12.97M	2.15M	15.02M	11.44M	-5.90M	1.90M	-12.97M
EBITDA Ratio	5.29%	7.47%	15.41%	12.01%	15.88%	12.16%	8.00%	9.36%	13.91%	11.25%	9.27%	8.62%	6.66%	5.13%	1.30%	5.54%	10.73%	8.33%	1.85%	12.06%	12.14%	2.28%	3.44%	-14.94%
Operating Income	-34.87M	-2.32M	89.51M	35.53M	78.35M	44.39M	5.75M	6.48M	48.63M	49.58M	35.30M	27.08M	16.22M	9.53M	669.00K	17.34M	18.22M	9.26M	-2.71M	10.55M	6.98M	-5.90M	-430.00K	-19.53M
Operating Income Ratio	-3.04%	-0.18%	7.91%	3.98%	8.73%	5.64%	0.80%	0.94%	10.04%	11.25%	9.27%	8.62%	6.61%	4.28%	0.31%	6.88%	8.55%	5.98%	-2.23%	8.51%	6.84%	-6.73%	-0.49%	-29.00%
Total Other Income/Expenses	14.76M	-130.00K	-23.50M	-6.18M	-4.42M	-8.78M	-6.63M	-8.43M	-2.39M	-1.08M	-270.00K	-51.00K	-133.00K	431.00K	523.00K	3.38M	6.05M	1.91M	651.00K	379.00K	565.00K	875.00K	-577.00K	-1.16M
Income Before Tax	-20.11M	-2.45M	66.01M	29.35M	73.93M	35.62M	-879.00K	-1.95M	46.24M	48.50M	35.03M	27.03M	16.09M	9.96M	1.19M	20.72M	24.28M	11.17M	-2.05M	10.93M	7.55M	-5.03M	-1.01M	-20.69M
Income Before Tax Ratio	-1.75%	-0.19%	5.83%	3.29%	8.24%	4.52%	-0.12%	-0.28%	9.54%	11.00%	9.20%	8.61%	6.55%	4.48%	0.56%	8.23%	11.39%	7.22%	-1.69%	8.82%	7.39%	-5.73%	-1.16%	-30.71%
Income Tax Expense	263.00K	-8.10M	-11.84M	-2.85M	12.60M	-2.11M	-21.48M	-2.55M	15.48M	17.99M	11.05M	10.87M	5.70M	5.07M	748.00K	8.00M	-19.02M	804.00K	20.00K	324.00K	242.00K	10.00K	160.00K	100.00K
Net Income	-20.37M	5.65M	77.85M	32.19M	61.34M	37.73M	20.61M	603.00K	30.76M	30.52M	23.98M	16.16M	10.39M	4.89M	444.00K	12.72M	43.30M	10.37M	-2.07M	10.60M	7.31M	-5.04M	-1.17M	-20.79M
Net Income Ratio	-1.78%	0.44%	6.88%	3.61%	6.84%	4.79%	2.88%	0.09%	6.35%	6.92%	6.30%	5.15%	4.23%	2.20%	0.21%	5.05%	20.32%	6.70%	-1.71%	8.55%	7.15%	-5.75%	-1.34%	-30.86%
EPS	-0.45	0.13	1.79	0.76	1.48	0.96	0.81	0.27	0.86	0.86	0.69	0.49	0.31	0.15	0.01	0.40	1.35	0.38	-0.08	0.43	0.32	-0.23	-0.11	-12.20
EPS Diluted	-0.45	0.12	1.62	0.74	1.43	0.93	0.79	0.26	0.84	0.83	0.67	0.47	0.30	0.15	0.01	0.38	1.28	0.36	-0.08	0.38	0.29	-0.23	-0.11	-12.20
Weighted Avg Shares Out	45.21M	44.40M	43.48M	42.58M	41.46M	39.24M	37.48M	36.16M	35.86M	35.65M	34.74M	33.31M	33.12M	32.65M	31.69M	32.08M	32.08M	27.35M	25.91M	24.85M	22.75M	21.73M	10.31M	1.70M
Weighted Avg Shares Out (Dil)	45.21M	45.89M	47.94M	43.74M	42.94M	40.56M	38.71M	36.86M	36.72M	36.62M	35.78M	34.21M	34.10M	33.51M	32.06M	33.11M	33.82M	28.90M	25.91M	27.72M	25.32M	21.73M	10.31M	1.70M

3 Russell 2000 Stocks to Buy at a 52-week Low in July

July 24, 2024investorplace.com

The Russell 2000 index tracks the performance of small-to-mid capitalization stocks. If anyone has been watching this captivating index, they would have seen a stark divergence between small-to-mid-cap and large-cap returns.

Omnicell (OMCL) Banks on Product Launches, Global Growth

July 3, 2024zacks.com

Omnicell (OMCL) remains a key player in automating and modernizing global medication management infrastructure.

Here's Why Omnicell (OMCL) Should be in Your Portfolio Now

June 10, 2024zacks.com

A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).

Omnicell (OMCL) Gains From New Offerings Amid Cost Woes

June 3, 2024zacks.com

With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.

Omnicell Supports Global Charity Mercy Ships with Pharmacy Technology Donation

May 6, 2024businesswire.com

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Supports Global Charity Mercy Ships with Pharmacy Technology Donation.

Omnicell (OMCL) Q1 Earnings Top Estimates, Revenues Down Y/Y

May 6, 2024zacks.com

Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.

Omnicell to Present at the BofA Securities 2024 Health Care Conference

May 3, 2024businesswire.com

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the BofA Securities 2024 Health Care Conference.

Omnicell, Inc. (OMCL) Q1 2024 Earnings Call Transcript

May 2, 2024seekingalpha.com

Omnicell, Inc. (NASDAQ:OMCL ) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Kathleen Nemeth – Senior Vice President-Investor Relations Randall Lipps – Founder, Chairman, President and Chief Executive Officer Nchacha Etta – Executive Vice President...

Omnicell (OMCL) Q1 Earnings and Revenues Top Estimates

May 2, 2024zacks.com

Omnicell (OMCL) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.08 per share. This compares to earnings of $0.39 per share a year ago.